Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6509953 | 0.82 | BCHE (0.54) | ALDH1A1SMN1; SMN2PKMBCHEACHE | |
| SCHEMBL6517918 | 0.82 | BCHE (0.54) | ALDH1A1SMN1; SMN2PKMBCHEACHE | |
| SCHEMBL6519828 | 0.82 | BCHE (0.54) | ALDH1A1SMN1; SMN2PKMBCHEACHE | |
| SCHEMBL20610741 | 0.77 | F2RL1 (0.51) | ALDH1A1PKMBCHEACHEEGFR | |
| SCHEMBL6803332 | 0.74 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2BCHEACHEEGFR | |
| SCHEMBL1616445 | 0.74 | STAT3 (0.43) | ALDH1A1SMN1; SMN2PKMGAA | |
| SCHEMBL28931265 | 0.74 | STAT3 (0.43) | ALDH1A1PKMGAALMNA | |
| SCHEMBL1681607 | 0.74 | STAT3 (0.43) | ALDH1A1PKMGAALMNA | |
| SCHEMBL8780852 | 0.72 | FKBP1A (0.53) | ALDH1A1SMN1; SMN2BCHEACHEEGFR | |
| SCHEMBL5870597 | 0.71 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2PKMBCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050192430-A1 | Linker arms for nanocrystals and compounds thereof | ROSENTHAL SANDRA J (US) | 2005-09-01 | — | — | US | disclosed |
| US-20030129590-A1 | Linker arms for nanocrystals and compounds thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-07-10 | — | — | US | disclosed |
| WO-2001090716-A2 | LINKER ARMS FOR NANOCRYSTALS AND COMPOUNDS THEREOF | VANDERBILT UNIVERSITY (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030129590-A1 | Linker arms for nanocrystals and compounds thereof | SCO2, NCL, NCAPH | ALDH1A1 2277/4885SMN1; SMN2 1359/4885PKM 3276/4885 |
| US-20050192430-A1 | Linker arms for nanocrystals and compounds thereof | NCL, CHN2, SCO2 | ALDH1A1 3030/4885SMN1; SMN2 1903/4885PKM 4211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.